• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Definium Therapeutics, Inc. - Common Shares (NQ:DFTX)

46.14 +1.75 (+3.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,782,246
Open 44.39
Bid (Size) 45.00 (100)
Ask (Size) 46.90 (200)
Prev. Close 44.39
Today's Range 44.30 - 46.18
52wk Range 14.62 - 49.20
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Definium Therapeutics Q2 Earnings Call Highlights ↗
August 06, 2026
Definium Therapeutics (NASDAQ:DFTX) said it expects to report top-line results from its Phase III VOYAGE study of DT120 ODT in generalized anxiety disorder during the week of Aug. 10, following... 
Via MarketBeat
Topics Earnings
Definium Therapeutics (NASDAQ:DFTX) Slides After Q2 Loss Misses Estimates on Warrant Charge ↗
August 06, 2026
Via Chartmill

Performance

YTD
+200.0%
+200.0%
1 Month
+3.7%
+3.7%
3 Month
+98.9%
+98.9%
6 Month
+183.9%
+183.9%
1 Year
+200.0%
+200.0%

More News

Read More
News headline image
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
August 06, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
August 05, 2026
From USA News Group
Via GlobeNewswire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
August 03, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
July 30, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
July 20, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
July 16, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
July 14, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
July 06, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
June 30, 2026
Via FinancialNewsMedia
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
June 30, 2026
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 25, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
June 23, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics, Inc. Announces Proposed Public Offering
June 22, 2026
From Definium Therapeutics, Inc.
Via Business Wire
Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session. ↗
June 22, 2026
Via Chartmill
Which stocks are moving on Monday? ↗
June 22, 2026
Via Chartmill
Monday's session: gap up and gap down stocks ↗
June 22, 2026
Via Chartmill
News headline image
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
June 22, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
June 21, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
June 15, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
June 01, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program ↗
May 22, 2026
Via MarketBeat
News headline image
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 21, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗
May 18, 2026
Via The Motley Fool

Frequently Asked Questions

Is Definium Therapeutics, Inc. - Common Shares publicly traded?
Yes, Definium Therapeutics, Inc. - Common Shares is publicly traded.
What exchange does Definium Therapeutics, Inc. - Common Shares trade on?
Definium Therapeutics, Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Definium Therapeutics, Inc. - Common Shares?
The ticker symbol for Definium Therapeutics, Inc. - Common Shares is DFTX on the Nasdaq Stock Market
What is the current price of Definium Therapeutics, Inc. - Common Shares?
The current price of Definium Therapeutics, Inc. - Common Shares is 46.14
When was Definium Therapeutics, Inc. - Common Shares last traded?
The last trade of Definium Therapeutics, Inc. - Common Shares was at 08/06/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap